Skip to Main Content

Advertisement

Skip Nav Destination

OnlineFirst

Research Article April 12 2022
HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma
Clin Cancer Res (2022)
Research Article April 12 2022
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
Clin Cancer Res (2022)
Research Article April 12 2022
Artificial Intelligence-Assisted Serial Analysis of Clinical Cancer Genomics Data Identifies Changing Treatment Recommendations and Therapeutic Targets
Clin Cancer Res (2022)
Research Article April 10 2022
The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
Clin Cancer Res (2022)
Research Article April 7 2022
Searching for Synergy: Chemotherapy and Checkpoint Inhibitors
Clin Cancer Res (2022)
Research Article April 7 2022
Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations
Clin Cancer Res (2022)
Research Article April 7 2022
Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma
Clin Cancer Res (2022)
Research Article April 7 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial
Clin Cancer Res (2022)
Research Article April 7 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Clin Cancer Res (2022)
Research Article April 7 2022
Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer
Clin Cancer Res (2022)
Research Article April 7 2022
A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect
Clin Cancer Res (2022)
Research Article April 4 2022
FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy
Clin Cancer Res (2022)
Research Article April 4 2022
One Size Does Not Fit All: Breast Cancer in Young Women
Clin Cancer Res (2022)
Research Article April 4 2022
Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?
Clin Cancer Res (2022)
Research Article March 30 2022
Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
Clin Cancer Res (2022)
Research Article March 30 2022
Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Clin Cancer Res (2022)
Research Article March 30 2022
Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis
Clin Cancer Res (2022)
Research Article March 28 2022
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Clin Cancer Res clincanres.2664.2021.
Research Article March 24 2022
Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Clin Cancer Res (2022)
Review Article March 22 2022
Neoadjuvant Approaches in Hepatocellular Carcinoma: There's No Time Like the Present
Clin Cancer Res (2022)
Research Article March 21 2022
RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition
Clin Cancer Res (2022)
Research Article March 21 2022
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Clin Cancer Res (2022)
Research Article March 21 2022
FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation
Clin Cancer Res (2022)
Research Article March 15 2022
AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma
Clin Cancer Res (2022)
Research Article February 24 2022
A prospective observational study of Active surveillance in primary desmoid fibromatosis
Clin Cancer Res clincanres.4205.2021.
Research Article February 21 2022
Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma
Clin Cancer Res (2022)
Research Article February 21 2022
FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy
Clin Cancer Res (2022)
Review Article February 21 2022
Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes
Clin Cancer Res (2022)
Research Article February 18 2022
Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study
Clin Cancer Res (2022)
Research Article February 11 2022
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
Clin Cancer Res (2022)
Research Article February 7 2022
Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
Clin Cancer Res (2022)
Research Article February 7 2022
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Clin Cancer Res (2022)
Research Article February 4 2022
The PD-L1/4-1BB bispecific Antibody-Anticalin fusion protein PRS-344/S095012 elicits strong T-cell stimulation in a tumor-localized manner
Clin Cancer Res clincanres.2762.2021.
Research Article January 31 2022
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1–High NSCLC
Clin Cancer Res (2022)
Research Article January 31 2022
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
Clin Cancer Res (2022)
Research Article January 28 2022
Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
Clin Cancer Res (2022)
Research Article January 28 2022
Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer
Clin Cancer Res (2022)
Research Article January 28 2022
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Clin Cancer Res (2022)
Research Article January 24 2022
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)
Clin Cancer Res (2022)
Research Article January 21 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
Clin Cancer Res (2022)
Research Article January 19 2022
Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)
Clin Cancer Res (2022)
Research Article January 14 2022
Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
Clin Cancer Res (2022)
Research Article December 13 2021
Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies
Clin Cancer Res (2021)
Research Article July 25 2016
GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models
Clin Cancer Res clincanres.0137.2016.
Page 3 of 3
Close Modal

or Create an Account

Close Modal
Close Modal